MedRod® Products
Registered Trademark Developed By Preclinapps
MedRod® for Chronic Dosing
In validated MedRod® implants the active compounds are dispersed in flexible, polymeric cylindrical matrix , typically covered by membrane or coating. The process results in elastic MedRod® where the compounds are safely immobilized and steadily released for several months. MedRod® implants are intended for in vitro or in vivo preclinical studies.
MedRod® Implants for Chronic Dosing in Preclinical Studies
MedRod® implants are designed for reliable, long-term chronic dosing in in vitro and in vivo preclinical studies. Utilizing a validated process, active compounds are dispersed within a flexible, polymer-based cylindrical matrix, typically encased in a specialized membrane or coating. This unique construction results in an elastic MedRod® implant that securely immobilizes active compounds, providing a consistent, controlled release over several months.
MedRod® sustained-release implants support study designs that require steady compound delivery without the need for frequent re-dosing. By offering a stable release profile in chronic dosing, MedRod® minimizes variability, enhances data quality, and reduces handling time, making it ideal for long-term pharmacology and toxicology studies.
Estrone (E1)
For mice and rats in metabolic and breast cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days, specific implants up to several years
Dose range: 0.02 µg – 5 µg/day
17β-estradiol (E2)
For mice and rats in metabolic and breast cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days, specific implants up to several years
Dose range: 0.25 µg – 15 µg/day
Dihydrotestosterone (DHT)
For mice and rats in metabolic and prostate cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days
Dose range: 10 µg – 100 µg/day
Progesterone (P4)
For mice and rats in metabolic and breast cancer xenograft, PDX and syngeneic studies.
Drug release: 50 – 150 days
Dose range: 25 µg – 250 µg/day
Testosterone (TE)
For mice and rats in metabolic and prostate cancer xenograft, PDX and syngeneic studies.
Drug release: At least 100 days
Dose range: 10 µg – 125 µg/day
Letrozole (LTZ)
For mice and rats in metabolic studies, breast and prostate cancer xenograft, PDX and syngeneic studies and studies related to aromatase inhibitors.
Drug release: At least 100 days, specific implants up to 6 months
Dose range:5 µg – 75 µg/day